- Home
- STT vs PODD Comparison
STT vs PODD Comparison
Compare STT & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STT
- PODD
- Stock Information
- Founded
- STT 1792
- PODD 2000
- Country
- STT United States
- PODD United States
- Employees
- STT N/A
- PODD N/A
- Industry
- STT Major Banks
- PODD Medical/Dental Instruments
- Sector
- STT Finance
- PODD Health Care
- Exchange
- STT Nasdaq
- PODD Nasdaq
- Market Cap
- STT 25.8B
- PODD 21.5B
- IPO Year
- STT N/A
- PODD 2007
- Fundamental
- Price
- STT $115.45
- PODD $330.77
- Analyst Decision
- STT Buy
- PODD Strong Buy
- Analyst Count
- STT 11
- PODD 18
- Target Price
- STT $116.18
- PODD $332.22
- AVG Volume (30 Days)
- STT 1.5M
- PODD 703.8K
- Earning Date
- STT 10-14-2025
- PODD 08-07-2025
- Dividend Yield
- STT 2.99%
- PODD N/A
- EPS Growth
- STT 67.51
- PODD N/A
- EPS
- STT 8.92
- PODD 3.32
- Revenue
- STT $13,323,000,000.00
- PODD $2,359,500,000.00
- Revenue This Year
- STT $6.71
- PODD $24.54
- Revenue Next Year
- STT $3.40
- PODD $17.48
- P/E Ratio
- STT $12.95
- PODD $99.54
- Revenue Growth
- STT 10.97
- PODD 26.00
- 52 Week Low
- STT $72.81
- PODD $180.31
- 52 Week High
- STT $115.65
- PODD $334.18
- Technical
- Relative Strength Index (RSI)
- STT 65.43
- PODD 68.80
- Support Level
- STT $110.27
- PODD $302.41
- Resistance Level
- STT $114.08
- PODD $334.18
- Average True Range (ATR)
- STT 1.98
- PODD 8.76
- MACD
- STT 0.05
- PODD 3.53
- Stochastic Oscillator
- STT 97.08
- PODD 94.09
About STT State Street Corporation
State Street is a leading provider of financial services, including investment servicing, investment management, and investment research and trading. With approximately $47 trillion in assets under custody and administration and $4.7 trillion assets under management as of Dec. 31, 2024, State Street operates globally in more than 100 geographic markets and employs about 53,000 worldwide.
About PODD Insulet Corporation
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetics are using it worldwide.